BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 104 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 0.44 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $56,000 | -53.3% | 14,777 | 0.0% | 0.00% | – |
| Q1 2019 | $120,000 | +0.8% | 14,777 | 0.0% | 0.00% | – |
| Q4 2018 | $119,000 | +5.3% | 14,777 | 0.0% | 0.00% | – |
| Q3 2018 | $113,000 | +32.9% | 14,777 | 0.0% | 0.00% | – |
| Q2 2018 | $85,000 | +21.4% | 14,777 | 0.0% | 0.00% | – |
| Q1 2018 | $70,000 | -94.1% | 14,777 | -87.2% | 0.00% | -100.0% |
| Q4 2015 | $1,188,000 | -8.3% | 115,116 | +1.3% | 0.00% | -20.0% |
| Q3 2015 | $1,295,000 | -27.2% | 113,606 | -4.6% | 0.01% | -16.7% |
| Q2 2015 | $1,778,000 | +70.5% | 119,106 | +3.1% | 0.01% | +50.0% |
| Q1 2015 | $1,043,000 | -19.7% | 115,496 | +8.1% | 0.00% | -20.0% |
| Q4 2014 | $1,299,000 | +28.0% | 106,806 | +2.9% | 0.01% | +25.0% |
| Q3 2014 | $1,015,000 | -23.3% | 103,806 | 0.0% | 0.00% | -20.0% |
| Q2 2014 | $1,324,000 | +21.8% | 103,806 | +1.1% | 0.01% | +25.0% |
| Q1 2014 | $1,087,000 | +11.7% | 102,706 | -19.8% | 0.00% | 0.0% |
| Q4 2013 | $973,000 | – | 128,076 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |